Dr. Reddy's Laboratories Management
Management Kriterienprüfungen 2/4
Dr. Reddy's Laboratories' CEO ist Erez Israeli, ernannt in Apr 2018, hat eine Amtszeit von 6.08 Jahren. besitzt direkt 0.041% der Aktien des Unternehmens, im Wert von ₹402.64M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.1 Jahre bzw. 3.8 Jahre.
Wichtige Informationen
Erez Israeli
Geschäftsführender
₹197.1m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | n/a |
| Amtszeit als Geschäftsführer | 6.5yrs |
| Eigentum des Geschäftsführers | 0.007% |
| Durchschnittliche Amtszeit des Managements | 6.5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 2.8yrs |
Jüngste Management Updates
Recent updates
If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Aug 19
Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet
Jul 30Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
Jun 23Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings
Jun 20Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00
May 26Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
May 10With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
May 06There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding
Apr 18Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 02Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?
Jan 19Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E
Jan 01Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet
Oct 21If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Oct 03Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt
Jul 14Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
Jun 24Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year
Jun 10Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
May 27Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00
May 13Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Apr 11If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Mar 06These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well
Jan 10If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Dec 05Is Dr. Reddy's Laboratories (NSE:DRREDDY) A Risky Investment?
Sep 28Do Dr. Reddy's Laboratories' (NSE:DRREDDY) Earnings Warrant Your Attention?
Aug 17Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹56b |
| Mar 31 2024 | ₹197m | n/a | ₹56b |
| Dec 31 2023 | n/a | n/a | ₹52b |
| Sep 30 2023 | n/a | n/a | ₹51b |
| Jun 30 2023 | n/a | n/a | ₹47b |
| Mar 31 2023 | ₹195m | n/a | ₹45b |
| Dec 31 2022 | n/a | n/a | ₹36b |
| Sep 30 2022 | n/a | n/a | ₹31b |
| Jun 30 2022 | n/a | n/a | ₹30b |
| Mar 31 2022 | ₹127m | n/a | ₹24b |
| Dec 31 2021 | n/a | n/a | ₹26b |
| Sep 30 2021 | n/a | n/a | ₹19b |
| Jun 30 2021 | n/a | n/a | ₹17b |
| Mar 31 2021 | ₹120m | n/a | ₹17b |
| Dec 31 2020 | n/a | n/a | ₹21b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹19b |
| Mar 31 2020 | ₹195m | ₹107m | ₹19b |
| Dec 31 2019 | n/a | n/a | ₹16b |
| Sep 30 2019 | n/a | n/a | ₹27b |
| Jun 30 2019 | n/a | n/a | ₹21b |
| Mar 31 2019 | ₹123m | n/a | ₹19b |
Vergütung im Vergleich zum Markt: ErezDie Gesamtvergütung ($USD2.35M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD1.03M).
Entschädigung vs. Einkommen: ErezDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Erez Israeli (56 yo)
6.5yrs
Amtszeit
₹197,090,000
Vergütung
Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019 and has been its Member of the Management Council since April 02, 2018. Mr. Israeli served as...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Chairman | 38.5yrs | ₹186.28m | 13.08% ₹ 147.0b | |
| Chairman of the Board & Member of the Management Council | 31.8yrs | ₹116.17m | 13.61% ₹ 153.0b | |
| CEO & Member of the Management Council | 6.5yrs | ₹197.09m | 0.0066% ₹ 73.6m | |
| CFO & Member of the Management Council | less than a year | ₹48.82m | 0.0057% ₹ 63.7m | |
| Global Head of Quality and Pharmacovigilance & Member of the Management Council | less than a year | ₹6.15m | keine Daten | |
| CEO of API & Services & Member of Management Council | no data | ₹41.90m | 0.0027% ₹ 30.1m | |
| CEO of Branded Markets - India & Emerging Countries and Member of Management Council | no data | ₹82.74m | 0.016% ₹ 176.8m | |
| EVP, Head of Corporate Communications | 7.3yrs | ₹65.21m | 0.0063% ₹ 71.4m | |
| Executive VP | 7.2yrs | ₹66.05m | keine Daten | |
| CEO of European Generics & Member of Management Council | no data | ₹63.09m | keine Daten | |
| Global Head of Integrated Product Development Organisation & Member of the Management Council | no data | ₹55.63m | 0.000020% ₹ 224.8k | |
| Global Head – Biologics & Member of the Management Council | no data | ₹34.59m | keine Daten |
6.5yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter
Erfahrenes Management: Das Managementteam von DRREDDY ist erfahren und erfahren (durchschnittliche Amtszeit: 6.1 Jahre).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Chairman | 38.5yrs | ₹186.28m | 13.08% ₹ 147.0b | |
| Chairman of the Board & Member of the Management Council | 31.8yrs | ₹116.17m | 13.61% ₹ 153.0b | |
| Member of the Scientific Advisory Board | no data | ₹8.36m | keine Daten | |
| Independent Director | 2.2yrs | ₹18.77m | keine Daten | |
| Independent Director | 5.8yrs | ₹13.34m | keine Daten | |
| Member of the Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Lead Independent Director | 6yrs | ₹17.10m | keine Daten | |
| Independent Director | 2.8yrs | ₹14.18m | keine Daten | |
| Independent Director | less than a year | ₹3.32m | keine Daten | |
| Independent Director | 1.8yrs | ₹8.25m | keine Daten | |
| Independent Director | 2.8yrs | ₹17.10m | keine Daten | |
| Independent Director | 1.4yrs | ₹16.09m | keine Daten |
2.8yrs
Durchschnittliche Betriebszugehörigkeit
64yo
Durchschnittliches Alter
Erfahrener Vorstand: DRREDDYDie Vorstandsmitglieder gelten nicht als erfahren ( 2.6 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.